The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
Open accessAbstract
INTRODUCTION: Chronic kidney disease (CKD) is a progressive disease of growing prevalence, posing serious concerns for global public health. While the economic burden of CKD is substantial, data on the cost of CKD is limited, despite growing pressures on healthcare systems. In this review, we summarise the available evidence in 31 countries and regions and compile a library of costing methodology and estimates of CKD management and disease-associated complications across 31 countries/regions within the Inside CKD programme. METHODS: We collected country/region-specific CKD costs via a pragmatic rapid literature review of local literature and engagement with local experts. We extracted cost data and definitions from identified sources for CKD stages G3a-5, kidney failure with replacement therapy by modality, covering haemodialysis, peritoneal dialysis, and kidney transplants, and disease-associated complications in local currency, converted to United States dollars (USD) and inflated to 2022. RESULTS: Annual direct costs associated with CKD management rose by an average factor of 4 in each country/region upon progression from stage G3a to G5. Mean annual costs per patient increased considerably more from early stages versus dialysis (stage G3a, mean: $3060 versus haemodialysis, mean: $57,334; peritoneal dialysis, mean: $49,490); with estimates for annual costs of transplant also substantially higher (incident: $75,326; subsequent: $16,672). The mean annual per patient costs of complications were $18,294 for myocardial infarction, $8463 for heart failure, $10,168 for stroke and $5975 for acute kidney injury. Costing definitions varied widely in granularity and/or definition across all countries/regions. CONCLUSION: Globally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,030
Epidemiology of chronic kidney disease: an update 2022
Kovesdy, C. P. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.003 · Cited by 2,973
Levey, A. S., de Jong, P. E., Coresh, J., El Nahas, M., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L., & Eckardt, K.-U. (2011) · Kidney International · doi:10.1038/ki.2010.483 · Cited by 2,345
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000102971.85504.7c · Cited by 1,144
Prevalence and Disease Burden of Chronic Kidney Disease
Lv, J.-C., & Zhang, L.-X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8871-2_1 · Cited by 1,103
The global burden of chronic kidney disease
Cockwell, P., & Fisher, L.-A. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32977-0 · Cited by 857
Reducing the costs of chronic kidney disease while delivering quality health care: a call to action
on behalf of the European Kidney Health Alliance, Vanholder, R., Annemans, L., Brown, E., Gansevoort, R., Gout-Zwart, J. J., Lameire, N., Morton, R. L., Oberbauer, R., Postma, M. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.63 · Cited by 368
Pagels, A. A., Söderkvist, B., Medin, C., Hylander, B., & Heiwe, S. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-71 · Cited by 271
Metadata
- Authors
- Jha, V., Al-Ghamdi, S. M. G., Li, G., Wu, M.-S., Stafylas, P., Retat, L., Card-Gowers, J., Barone, S., Cabrera, C., & Garcia Sanchez, J. J.
- Venue
- Advances in Therapy
- Published
- 2023-07-26
- Volume
- 40
- Issue
- 10
- Pages
- 4405-4420
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W4385263761
- Cited by
- 279
- References
- 21
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme. https://app.cochat.ai/papers/10.1007/s12325-023-02608-9
- The paper
- Jha, V., Al-Ghamdi, S. M. G., Li, G., Wu, M.-S., Stafylas, P., Retat, L., Card-Gowers, J., Barone, S., Cabrera, C., & Garcia Sanchez, J. J. (2023). Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme. Advances in Therapy. https://doi.org/10.1007/s12325-023-02608-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.